再生医学领域已经见证了来自多种来源的诱导多能干细胞(iPSC)的出现的显著进步。其中,尿液来源的诱导多能干细胞(u-iPSCs)由于其非侵入性和对患者友好的获取方法而受到广泛关注。这篇综述手稿探讨了u-iPSCs在推进精准医学中的潜力和应用。特别是在药物测试领域,疾病建模,和细胞疗法。U-iPSC是通过尿液样本中发现的体细胞的重编程产生的,提供患者特异性多能细胞的独特和可再生来源。它们在药物测试中的应用彻底改变了制药行业,为药物筛选提供了个性化的平台,毒性评估,和疗效评价。具有不同遗传背景的u-iPSC的可用性促进了定制治疗方法的发展。尽量减少不良反应,优化治疗结果。此外,u-iPSCs在疾病建模中表现出显著的功效,允许研究人员在体外概括患者特异性病理。这不仅增强了我们对疾病机制的理解,而且是药物发现和开发的宝贵工具。此外,基于u-iPSC的疾病模型为研究罕见和遗传复杂的疾病提供了一个平台,传统的研究方法往往服务不足。u-iPSC的多功能性延伸到细胞治疗应用,他们对再生医学有着巨大的希望。它们分化为各种细胞类型的潜力,包括神经元,心肌细胞,和肝细胞,能够开发患者特异性细胞替代疗法。这种个性化的方法可以彻底改变退行性疾病的治疗,器官衰竭,和组织损伤,通过最大限度地减少免疫排斥反应和优化治疗结果。然而,几个挑战和考虑,例如重新编程协议的标准化,基因组稳定性,和可扩展性,必须解决的问题是充分利用u-iPSCs在精准医学中的潜力。总之,这篇综述强调了u-iPSCs对推进精准医疗的变革影响,并强调了利用这一创新技术改善医疗结果的未来前景和挑战.
The field of regenerative medicine has witnessed remarkable advancements with the emergence of induced pluripotent stem cells (iPSCs) derived from a variety of sources. Among these, urine-derived induced pluripotent stem cells (u-iPSCs) have garnered substantial attention due to their non-invasive and patient-friendly acquisition method. This review manuscript delves into the potential and application of u-iPSCs in advancing precision medicine, particularly in the realms of drug testing, disease modeling, and cell therapy. U-iPSCs are generated through the reprogramming of somatic cells found in urine samples, offering a unique and renewable source of patient-specific pluripotent cells. Their utility in drug testing has revolutionized the pharmaceutical industry by providing personalized platforms for drug screening, toxicity assessment, and efficacy evaluation. The availability of u-iPSCs with diverse genetic backgrounds facilitates the development of tailored therapeutic approaches, minimizing adverse effects and optimizing treatment outcomes. Furthermore, u-iPSCs have demonstrated remarkable efficacy in disease modeling, allowing researchers to recapitulate patient-specific pathologies in vitro. This not only enhances our understanding of disease mechanisms but also serves as a valuable tool for drug discovery and development. In addition, u-iPSC-based disease models offer a platform for studying rare and genetically complex diseases, often underserved by traditional research methods. The versatility of u-iPSCs extends to cell therapy applications, where they hold immense promise for regenerative medicine. Their potential to differentiate into various cell types, including neurons, cardiomyocytes, and hepatocytes, enables the development of patient-specific cell replacement therapies. This personalized approach can revolutionize the treatment of degenerative diseases, organ failure, and tissue damage by minimizing immune rejection and optimizing therapeutic outcomes. However, several challenges and considerations, such as standardization of reprogramming protocols, genomic stability, and scalability, must be addressed to fully exploit u-iPSCs\' potential in precision medicine. In conclusion, this review underscores the transformative impact of u-iPSCs on advancing precision medicine and highlights the future prospects and challenges in harnessing this innovative technology for improved healthcare outcomes.